Total Valuation
BioRegenx has a market cap or net worth of $7.29M. The enterprise value is $10.18M.
Market Cap$7.29M
Enterprise Value$10.18M
Share Statistics
BioRegenx has 971,575,200 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding971,575,200
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
BioRegenx’s return on equity (ROE) is 0.34 and return on invested capital (ROIC) is 31.98%.
Return on Equity (ROE)0.34
Return on Assets (ROA)-3.76
Return on Invested Capital (ROIC)31.98%
Return on Capital Employed (ROCE)0.14
Revenue Per Employee309.09K
Profits Per Employee-257.26K
Employee Count6
Asset Turnover4.51
Inventory Turnover3.28
Valuation Ratios
The current PE Ratio of BioRegenx is ―. BioRegenx’s PEG ratio is 0.09.
PE Ratio―
PS Ratio6.68
PB Ratio-2.73
Price to Fair Value-2.73
Price to FCF413.85
Price to Operating Cash Flow260.47
PEG Ratio0.09
Income Statement
In the last 12 months, BioRegenx had revenue of 1.85M and earned -1.54M in profits. Earnings per share was >-0.01.
Revenue1.85M
Gross Profit1.50M
Operating Income-518.99K
Pretax Income-1.54M
Net Income-1.54M
EBITDA-443.92K
Earnings Per Share (EPS)>-0.01
Cash Flow
In the last 12 months, operating cash flow was 27.91K and capital expenditures -9.06K, giving a free cash flow of 18.85K billion.
Operating Cash Flow27.91K
Free Cash Flow18.85K
Free Cash Flow per Share<0.01
Dividends & Yields
BioRegenx pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.09
52-Week Price Change-50.00%
50-Day Moving Average0.01
200-Day Moving Average0.01
Relative Strength Index (RSI)42.88
Average Volume (3m)59.55K
Important Dates
BioRegenx upcoming earnings date is Jan 28, 2020, Before Open (Confirmed).
Last Earnings DateOct 22, 2019
Next Earnings DateJan 28, 2020
Ex-Dividend Date―
Financial Position
BioRegenx as a current ratio of 0.06, with Debt / Equity ratio of -47.77%
Current Ratio0.06
Quick Ratio0.04
Debt to Market Cap0.18
Net Debt to EBITDA-4.83
Interest Coverage Ratio1.73
Taxes
In the past 12 months, BioRegenx has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
BioRegenx EV to EBITDA ratio is -32.72, with an EV/FCF ratio of 485.55.
EV to Sales7.83
EV to EBITDA-32.72
EV to Free Cash Flow485.55
EV to Operating Cash Flow372.71
Balance Sheet
BioRegenx has $45.81K in cash and marketable securities with $2.17M in debt, giving a net cash position of -$2.12M billion.
Cash & Marketable Securities$45.81K
Total Debt$2.17M
Net Cash-$2.12M
Net Cash Per Share>-$0.01
Tangible Book Value Per Share>-$0.01
Margins
Gross margin is 81.90%, with operating margin of -27.99%, and net profit margin of -83.23%.
Gross Margin81.90%
Operating Margin-27.99%
Pretax Margin-83.23%
Net Profit Margin-83.23%
EBITDA Margin-23.94%
EBIT Margin-27.99%
Analyst Forecast
The average price target for BioRegenx is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast-23.43%
EPS Growth Forecast93.36%